Acute respiratory distress syndrome

Acute Respiratory Distress Syndrome - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 30, 2019
Health, Pharmaceutical, Medicine, Medical specialties, Health, Intensive care medicine, Respiratory diseases, Pharmacology, Respiratory distress syndrome, Infant respiratory distress syndrome, Acute respiratory distress syndrome, Combination therapy, Respiratory system

The report covers pipeline activity across the complete product development cycle i.e.

Key Points: 
  • The report covers pipeline activity across the complete product development cycle i.e.
  • clinical, pre-clinical and discovery stages for the Acute Respiratory Distress Syndrome
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Acute Respiratory Distress Syndrome

Windtree Therapeutics and CVie Therapeutics Announce Merger to Create a Global Acute Care Company Targeting Cardiovascular and Respiratory Diseases

Retrieved on: 
Friday, December 21, 2018
Respiratory distress syndrome, Medicine, Acute respiratory distress syndrome, Health care, Health

The combined company, which will retain the name Windtree Therapeutics, will be a fully-integrated and diversified acute care company with four mid-to-late clinical stage product assets and multiple preclinical assets and programs.

Key Points: 
  • The combined company, which will retain the name Windtree Therapeutics, will be a fully-integrated and diversified acute care company with four mid-to-late clinical stage product assets and multiple preclinical assets and programs.
  • "This CVie merger is highly complementary and successfully meets our goal to create a company with multiple high-quality product assets focused on significant unmet medical needs in important acute cardiovascular and acute respiratory markets," commented Craig Fraser, President and Chief Executive Officer of Windtree.
  • Furthermore, as a potentially transformative therapy for acute Respiratory Distress Syndrome, AEROSURF is a highly attractive program with significant potential.
  • Windtree Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novelsurfactant therapies for respiratory diseases and other potential applications.

Doctors And Machines Combine Intelligence To Prevent Deadly Lung Failure

Retrieved on: 
Monday, October 22, 2018
Intensive care medicine, Medicine, Respiratory physiology, Acute respiratory distress syndrome, Artificial intelligence, Technology, Health

NEW YORK, Oct. 22, 2018 /PRNewswire/ -- A new artificial intelligence (AI) tool is being built to help doctors better identify and treat a deadly, but under-recognized, form of lung failure.

Key Points: 
  • NEW YORK, Oct. 22, 2018 /PRNewswire/ -- A new artificial intelligence (AI) tool is being built to help doctors better identify and treat a deadly, but under-recognized, form of lung failure.
  • "ARDS is under-recognized because these patients are often extremely ill and have other life-threatening conditions, such as shock, pneumonia, or trauma.
  • "By using new technology we hope to help clinicians identify ARDS as early as possible, when treatment may be most effective."
  • For more information, please visit www.einstein.yu.edu , read our blog , followus on Twitter , like us on Facebook ,and view us on YouTube .

Global Nitric Oxide Therapy Systems (Portable & Fixed) Market 2017-2026 - Market is Expected to Expand at a CAGR of 5.19%

Retrieved on: 
Thursday, June 14, 2018
Neurochemistry, Chemistry, Cell signaling, NMDA receptor antagonists, Gaseous signaling molecules, Nitrogen cycle, GABAA receptor positive allosteric modulators, Oxides, Nitric oxide, Acute respiratory distress syndrome, Ketamine, Biological functions of nitric oxide

The global nitric oxide therapy systems market is expected to expand at a CAGR of 5.19% from 2017 to 2026.

Key Points: 
  • The global nitric oxide therapy systems market is expected to expand at a CAGR of 5.19% from 2017 to 2026.
  • Durability and lightweight are the meritorious features that increase the demand for portable nitric oxide therapy systems.
  • North America is the market leader in nitric oxide therapy systems due to the rising prevalence of acute respiratory distress syndrome in the adult population and the presence of key players actively engaged in the manufacturing of nitric oxide therapy systems.
  • Competitive market formed due to the emergence of local providers of nitric oxide therapy systems contribute to the growth of Asia Pacific market.

Extracorporeal CO2 Removal Market to be Worth US$ 110.0 Mn by 2026, Says TMR

Retrieved on: 
Thursday, May 17, 2018
Medicine, Intensive care medicine, Health, Transparency Market Research, Respiratory distress syndrome, Acute respiratory distress syndrome, Infant respiratory distress syndrome

Transparency Market Research (TMR) has published a new report titled, " Extracorporeal CO2 Removal Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026".

Key Points: 
  • Transparency Market Research (TMR) has published a new report titled, " Extracorporeal CO2 Removal Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026".
  • Rise in demand for minimally invasive ventilation is anticipated to propel the extracorporeal CO2 removal market during the forecast period.
  • The surgical centers segment is projected to hold substantial share of the global extracorporeal CO2 removal market during the forecast period.
  • More Trending Reports by Transparency Market Research:
    Acute Respiratory Distress Syndrome Devices Market: https://www.transparencymarketresearch.com/acute-respiratory-distress-sy...
    Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services.